Skip to content

Nektar Therapeutics NKTR Other Non-Current Assets

Other Non-Current Assets at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.13B+52.9%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$8.52M+16.0%
Immunome logo
ImmunomeIMNM
$5.36M+23.4%
Vera Therapeutics logo
Vera TherapeuticsVERA
$5.94M
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$8.29M+1,846%
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.25B+1,531%
Enterprise value$2.33B+874%
P/S40.5×+38.9×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's other non-current assets?
Nektar Therapeutics (NKTR) reported other non-current assets of $11.24M in Q1 2026.
How has Nektar Therapeutics's other non-current assets changed year-over-year?
Nektar Therapeutics's other non-current assets increased by 108.4% year-over-year, from $5.39M to $11.24M.
What is the long-term trend for Nektar Therapeutics's other non-current assets?
Over 5 years (2020 to 2025), Nektar Therapeutics's other non-current assets has grown at a 57.5% compound annual growth rate (CAGR), from $1.46M to $14.14M.
What does other non-current assets mean?
This category captures long-term assets that do not fit into standard classifications like property, plant, equipment, or intangible assets. It may include long-term deposits, deferred tax assets, or other miscellaneous non-current investments. It represents the residual value of long-term resources held by the company.